Mark J. DiNubile, MD FIDSA, has recently joined BioAegis Therapeutics as our Chief Medical Officer to propel us forward into late-stage clinical development. He brings to the table the rare combination of clinical and research expertise along with broad pharmaceutical industry experience, coupled with his long-standing dedication to elucidating the clinical utility of plasma gelsolin. Mark is a board-certified physician in Internal Medicine and the subspecialty of Infectious Diseases. He joins BioAegis after 16 years at Merck & Co., Inc. where he was primarily focused on the therapeutic areas of Infectious Diseases and Vaccines. He has extensively published on a diverse spectrum of medical and scientific topics.
Mark graduated from the University of Pennsylvania summa cum laude with distinction in his major field of study (Psychology). He then attended Yale University School of Medicine, followed by completion of internship and residency at the Hospital of the University of Pennsylvania. As a fellow at Harvard, he completed his clinical Infectious Diseases requirements at the Brigham & Women’s Hospital followed by Hematology research focusing on neutrophil motility and phagocytosis at the Massachusetts General Hospital. During this period, he worked in the laboratory of our founding scientist Dr. Thomas P. Stossel. For the ensuing 16 years, Mark cared for patients in the ambulatory and hospital setting; taught medical students, house officers and fellows; chaired the hospital Pharmacy and Therapeutics Committee; initiated an antibiotic-stewardship program; and pursued clinical investigation and basic research, largely related to host defense and immunosuppression.